HomeHealthcare & Life SciencesPharmaceuticals Myasthenia Gravis Treatment Market

United Kingdom Myasthenia Gravis Treatment Market Size & Outlook, 2025-2033


United Kingdom Myasthenia Gravis Treatment Market Insights

  • Reed Intelligence analysis indicates that the United Kingdom Myasthenia Gravis Treatment Market size, valued at USD 114.91 Million in 2024, is expected to expand to USD 274.11 Million by 2033.
  • The United Kingdom market is forecasted to expand at a CAGR of 10.09% spanning 2026–2033.
  • Ocular MG  held the leading position among By Type segments in 2024, based on market size.
  • Congenital MG  is projected to post the fastest growth rate, sustaining its position as the most attractive By Type segment during the forecast horizon.

Other Key Findings


  • In 2024, United Kingdom accounted for 5.45% of the global Myasthenia Gravis Treatment Market size.
  • By 2033, United States is expected to lead the global Myasthenia Gravis Treatment Market in terms of market size.
  • Within Europe, Germany is projected to dominate the regional Myasthenia Gravis Treatment Market size by 2033.
  • Benelux is identified as the fastest-growing market in Europe, anticipated to reach USD 97.67 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 114.91 Million
Market Size In 2033 USD 274.11 Million
Largest segment Ocular MG 
Units Revenue in USD Million
CAGR 10.09% (2025-2033)
Segmnetation Covered
By Type
  1. Ocular MG 
  2. Congenital MG 
  3. Transient Neonatal MG
By Treatment
  1. Medication 
  2. Surgery 
  3. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
  4. Plasmapheresis and Intravenous Immunoglobulin 
  5. Others
By End-User
  1. Hospitals 
  2. Clinics 
  3. Academic Research Institutes 
  4. Others
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports